Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows
News
Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives of men with metastatic castration-resistant prostate cancer (mCRPC) in ... Read more